News
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...
PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 - CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback